[go: up one dir, main page]

DK2623507T3 - Morpholinonukleinsyrederivat - Google Patents

Morpholinonukleinsyrederivat

Info

Publication number
DK2623507T3
DK2623507T3 DK11829283.8T DK11829283T DK2623507T3 DK 2623507 T3 DK2623507 T3 DK 2623507T3 DK 11829283 T DK11829283 T DK 11829283T DK 2623507 T3 DK2623507 T3 DK 2623507T3
Authority
DK
Denmark
Prior art keywords
acid derivative
morpholinonucleic
morpholinonucleic acid
derivative
acid
Prior art date
Application number
DK11829283.8T
Other languages
English (en)
Inventor
Toshihiro Ueda
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of DK2623507T3 publication Critical patent/DK2623507T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK11829283.8T 2010-09-30 2011-09-29 Morpholinonukleinsyrederivat DK2623507T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010220865 2010-09-30
PCT/JP2011/072407 WO2012043730A1 (ja) 2010-09-30 2011-09-29 モルホリノ核酸誘導体

Publications (1)

Publication Number Publication Date
DK2623507T3 true DK2623507T3 (da) 2017-01-02

Family

ID=45893168

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11829283.8T DK2623507T3 (da) 2010-09-30 2011-09-29 Morpholinonukleinsyrederivat

Country Status (18)

Country Link
US (1) US8969551B2 (da)
EP (1) EP2623507B1 (da)
JP (1) JP5831455B2 (da)
KR (1) KR101764462B1 (da)
CN (1) CN103154009B (da)
CA (1) CA2813183C (da)
CY (1) CY1118435T1 (da)
DK (1) DK2623507T3 (da)
ES (1) ES2607603T3 (da)
HR (1) HRP20170028T1 (da)
HU (1) HUE030292T2 (da)
LT (1) LT2623507T (da)
PL (1) PL2623507T3 (da)
PT (1) PT2623507T (da)
RS (1) RS55610B1 (da)
SI (1) SI2623507T1 (da)
SM (2) SMT201700038T1 (da)
WO (1) WO2012043730A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
TR201902952T4 (tr) 2008-10-24 2019-03-21 Sarepta Therapeutics Inc Dmd için ekson atlama bileşimleri.
CA2780563C (en) 2009-11-12 2025-05-06 Univ Western Australia Antisense Molecules and Methods for Treating Pathologies
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CN108864192A (zh) 2011-11-18 2018-11-23 萨勒普塔医疗公司 功能改性的寡核苷酸及其亚单元
US9920085B2 (en) 2012-03-20 2018-03-20 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
NZ775701A (en) 2013-03-14 2022-08-26 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
NZ732507A (en) 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
CN105228999B (zh) 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
CN105793422B (zh) 2013-09-05 2020-03-03 萨罗塔治疗公司(美国) 酸性α-葡糖苷酶中反义诱导的外显子2纳入
JP6901966B2 (ja) 2014-05-16 2021-07-14 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
JP6687542B2 (ja) 2014-05-19 2020-04-22 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
CN106795186B (zh) 2014-10-14 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
AU2015372560B2 (en) 2014-12-31 2021-12-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
NZ737757A (en) 2015-05-19 2023-07-28 Sarepta Therapeutics Inc Peptide oligonucleotide conjugates
WO2016196670A1 (en) 2015-06-01 2016-12-08 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
PE20231843A1 (es) 2015-08-05 2023-11-21 Eisai Randd Man Co Ltd Reactivos quirales para la preparacion de oligomeros homogeneos
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
US20190030176A1 (en) 2015-12-15 2019-01-31 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US11142764B2 (en) 2015-12-23 2021-10-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2017112885A1 (en) 2015-12-23 2017-06-29 David Greenberg Antisense antibacterial compounds and methods
EP3445405A4 (en) 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERS AND METHOD FOR USE THEREOF TO TREAT DISEASES RELATING TO THE ACID ALPHA GLUCOSIDASE GENE
CN109477109B (zh) 2016-04-29 2022-09-23 萨勒普塔医疗公司 靶向人lmna的寡核苷酸类似物
BR112018074299A2 (pt) 2016-05-24 2019-03-12 Sarepta Therapeutics, Inc. composições farmacêuticas compreendendo eteplirsen
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
HRP20240583T1 (hr) 2016-05-24 2024-07-19 Sarepta Therapeutics, Inc. Postupci za pripremu fosforodiamidat morfolino oligomera
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3464305B1 (en) 2016-05-24 2024-08-21 Sarepta Therapeutics, Inc. Processes for preparing oligomers
AU2017270598B2 (en) 2016-05-24 2022-12-01 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
EP3515445A4 (en) * 2016-09-20 2020-05-27 The Regents of The University of Colorado, A Body Corporate SYNTHESIS OF BACKBONE-MODIFIED MORPHOLINO-OLIGONUCLEOTIDES AND CHIMERES WITH THE AID OF PHOSPHORAMIDITE CHEMISTRY
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
US20200362339A1 (en) * 2017-09-25 2020-11-19 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
US11560401B2 (en) 2018-05-10 2023-01-24 Nippon Shinyaku Co., Ltd. Method for preparing oligonucleic acid compound
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
US20230018780A1 (en) 2019-11-13 2023-01-19 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
CN114981280A (zh) 2019-11-13 2022-08-30 日本新药株式会社 寡核苷酸化合物的制造方法
JP7703579B2 (ja) * 2020-07-10 2025-07-07 チャンヂョウ シンザオール ファーマシューティカルズ カンパニー リミテッド オリゴヌクレオチドを調製するための方法
CA3218264A1 (en) * 2021-04-28 2022-11-03 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
AU2022267324A1 (en) 2021-04-30 2023-12-14 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
JP2024539223A (ja) 2021-10-22 2024-10-28 サレプタ セラピューティクス, インコーポレイテッド 末梢ミエリンタンパク質22関連疾患の処置のためのモルフォリノオリゴマー
JPWO2023127918A1 (da) 2021-12-27 2023-07-06
IL315344A (en) * 2022-03-01 2024-10-01 Eisai R&D Man Co Ltd Bis-protected, activated guanine monomers
EP4493693A1 (en) 2022-03-17 2025-01-22 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312834T1 (de) 1989-12-20 2005-12-15 Avi Biopharma Inc Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten
JP2005255530A (ja) * 2004-03-09 2005-09-22 Japan Science & Technology Agency 2−チオウリジン誘導体
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
WO2009064471A1 (en) * 2007-11-15 2009-05-22 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits

Also Published As

Publication number Publication date
EP2623507A4 (en) 2014-03-19
KR20130143045A (ko) 2013-12-30
RS55610B1 (sr) 2017-06-30
CA2813183A1 (en) 2012-04-05
CN103154009A (zh) 2013-06-12
CY1118435T1 (el) 2017-06-28
PT2623507T (pt) 2016-12-23
EP2623507B1 (en) 2016-11-02
SMT201700038T1 (it) 2017-03-08
LT2623507T (lt) 2017-01-25
JP5831455B2 (ja) 2015-12-09
ES2607603T3 (es) 2017-04-03
HUE030292T2 (en) 2017-04-28
EP2623507A1 (en) 2013-08-07
SMT201700038B (it) 2017-03-08
PL2623507T3 (pl) 2017-03-31
CA2813183C (en) 2017-09-19
KR101764462B1 (ko) 2017-08-02
JPWO2012043730A1 (ja) 2014-02-24
CN103154009B (zh) 2015-06-10
US8969551B2 (en) 2015-03-03
HRP20170028T1 (hr) 2017-03-24
SI2623507T1 (sl) 2017-04-26
WO2012043730A1 (ja) 2012-04-05
US20130197220A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
DK2623507T3 (da) Morpholinonukleinsyrederivat
DK2562155T3 (da) Hydroxaminsyrederivat
PL2614063T3 (pl) Podstawione imidazopirydazyny
DK3225404T3 (da) Fluidpatron
EP2578585A4 (en) Purinone derivative
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
EP2659556A4 (en) PRE-CHAMBER IGNITION SYSTEM
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2553434A4 (en) FLUOROMETRIC PROBE
EP2568873A4 (en) VACUUM RETRACTOR
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
EP2591235A4 (en) FUSION METAL WHEEL
DE112011104226A5 (de) Käfigmutter
EP2623153A4 (en) INTERCONNECTS
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011102080A5 (de) Kupplungszentralausrücker
DE112011101226A5 (de) Linearwegmesssystem
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102010038420A8 (de) Reinigungungsvorrichtung
EP2584243A4 (en) INTERCONNECTS
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2571003A4 (en) RISK CALCULATION APPARATUS